A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults

Start 13 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 22806

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other

Status Ongoing, recruiting

Participants planned 72

Countries 1

Sites 1

atrial fibrillation

Key facts

Sponsor: Bayer AG
Participant type: Healthy volunteers
Age range: 18-64 years
Gender: Male and Female
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trial duration: 13 May 2026 → ongoing
Decision date (initial): 2026-04-15
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

atrial fibrillation

Version	Level	Code	Term	System organ class
22.1	LLT	10055221	Ischemic stroke	10029205
20.1	LLT	10072760	Transient ischemic attack	10029205
28.1	PT	10003658	Atrial fibrillation	100000004849

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bayer AG

Sponsor organisation: Bayer AG
Address: -
City: Leverkusen
Postcode: 51368
Country: Germany

Scientific contact point

Organisation: Bayer AG
Contact name: Therapeutic Area Head

Public contact point

Organisation: Bayer AG
Contact name: Therapeutic Area Head

Locations

1 EU/EEA country · 1 investigational sites

By country

Country	MS status	Planned subjects	Sites
Germany	Ongoing, recruiting	72	1
Rest of world	—	0	—

Investigational sites

Germany

1 site · Ongoing, recruiting

CRS Clinical Research Services Berlin GmbH

Patient Visits, Siemensdamm 65, Siemensstadt, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country	Trial start	Trial end	Recruitment start	Recruitment end	Early termination
Germany	2026-05-13		2026-05-20

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#	Type	Code	Submitted	Reference MS	Conclusion	Decision date
1	INITIAL	IN	2026-02-18	Germany	Acceptable 2026-04-14	2026-04-15